Antiarrhythmic efficacy of azimilide in patients with atrial fibrillation. Maintenance of sinus rhythm after conversion to sinus rhythm - 17/08/11
, Peter Kowey, MD b, Stuart Connolly, MD c, Richard L. Page, MD d, Charles Kerr, MD e, William E. Wilkinson, PhD aFor the A-COMET-I Investigators
This study was sponsored by Procter & Gamble Pharmaceuticals, Mason, OH. At the time it was conducted, all authors were members of the scientific advisory committee for it and were either consultants or investigators for Procter & Gamble Pharmaceuticals. At the time the manuscript was written, Dr Pritchett, Dr Kowey, and Dr Wilkinson were consultants for Procter & Gamble Pharmaceuticals, and Dr Page received grant support from Procter & Gamble Pharmaceuticals through the University of Washington.
Riassunto |
Background |
Azimilide dihydrochloride (azimilide) is an investigational antiarrhythmic drug that has been tested in patients with a variety of arrhythmias. In patients with atrial fibrillation, it has shown excellent efficacy in some previous trials and minimal efficacy in others.
Methods |
Patients who had symptomatic atrial fibrillation for >48 hours but <6 months were eligible for this multicenter, randomized, placebo-controlled clinical trial. Patients were admitted to a hospital and randomly assigned to receive either azimilide 125 mg or a matched placebo twice daily for 3 days and then once daily. Patients who were in sinus rhythm spontaneously or had sinus rhythm restored by electric cardioversion on day 4 were discharged from the hospital. Recurrence of atrial fibrillation was documented by electrocardiogram. In the primary efficacy analysis, time to recurrence in the 2 treatment groups was compared with the log-rank test in the subgroup of patients with structural heart disease. Safety was assessed as deaths, adverse events, and serious adverse events.
Results |
A total of 446 patients were randomized in the study; 314 were in the subgroup with structural heart disease. The median time to arrhythmia recurrence in both treatment groups with structural heart disease was 13 days, and the difference between treatments was not significant (P = .4596, n = 314). The relative risk for recurrence (placebo:azimilide) was 1.104 (95% CI 0.849-1.436). There was 1 death in the placebo group and 3 in the azimilide group.
Conclusions |
Azimilide did not demonstrate clinically important or statistically significant efficacy in reducing the risk for arrhythmia recurrence in patients with structural heart disease who were in atrial fibrillation and converted to sinus rhythm.
Il testo completo di questo articolo è disponibile in PDF.Mappa
Vol 151 - N° 5
P. 1043-1049 - Maggio 2006 Ritorno al numero
Articolo precedente
- Effects of a statewide physician-led quality-improvement program on the quality of cardiac care
- J. Richard Goss, Charles Maynard, Gabriel S. Aldea, Miriam Marcus-Smith, Richard W. Whitten, Gilbert Johnston, Richard C. Phillips, Mark Reisman, Ann Kelley, Richard P. Anderson, for the Clinical Outcomes Assessment Program (COAP)
- Randomized comparison of simultaneous biventricular stimulation versus optimized interventricular delay in cardiac resynchronization therapy : The Resynchronization for the HemodYnamic Treatment for Heart Failure Management II implantable cardioverter defibrillator (RHYTHM II ICD) study
- Giuseppe Boriani, Cord Paul Müller, Karl Heinz Seidl, Rainer Grove, Jürgen Vogt, Wilfried Danschel, Andreas Schuchert, Pierre Djiane, Mauro Biffi, Thorsten Becker, Christophe Bailleul, Hans Joachim Trappe, for the Resynchronization for the HemodYnamic Treatment for Heart Failure Management II (RHYTHM II) investigators
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?